Memorial Sloan-Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

At the seventh annual seminar for high school students and teachers, investigators discuss how cutting-edge biomedical research may ultimately contribute to better treatments for cancer patients.

Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

Medical oncologist Mark Kris discusses how cancer experts are working to train IBM Watson to help assist medical professionals.

New research suggests that analyzing genetic changes found in the bloodstream may help doctors predict which chemotherapy regimens will work for some patients.

A team from Memorial Sloan-Kettering has found that the makeup of immune cells in a lung tumor and in tissue surrounding a tumor can predict whether the cancer will recur after surgery.

Memorial Sloan-Kettering researchers have shown for the first time that administering a growth factor called interleukin-7 can help patients regenerate T cells more quickly after stem cell transplantation.